Russian pharmaceutical exports to EU rise 66% in July

Monthly shipments reach a ten-month high

Russian pharmaceutical exports to the European Union increased sharply in July, reaching their highest monthly value since September 2025. The bloc imported €5.99 million of medicines from Russia, according to Eurostat data cited by RIA Novosti and reported by Rambler Finance.

The value of July shipments rose 66% from the previous month and 36% from the same month a year earlier. The two comparisons indicate that the increase was not solely the result of a weak preceding month: Russian suppliers also exceeded their year-earlier sales to the EU by more than one-third.

The available data, however, describe trade by value rather than physical volume. They therefore do not show how much of the increase came from larger quantities, changes in the product mix or higher prices. No breakdown by medicine category, exporting company or EU destination was provided.

Six-month purchases also increased

Across the six-month period covered by the report, EU countries purchased €22 million of medicines from Russia. That was 21% more than in the comparable period a year earlier. July alone accounted for a substantial portion of that reported total, underlining how strongly the latest month contributed to the increase.

The six-month gain suggests that trade was already running above the previous year's level before the July acceleration. Still, a single monthly peak does not establish a durable trend. Confirmation would require subsequent data showing whether orders remained elevated after July and whether growth extended across several EU markets and pharmaceutical categories.

Trade remains heavily weighted toward EU suppliers

The bilateral pharmaceutical trade relationship remains highly uneven. The European Union reduced its medicine exports to Russia by 5% year on year, but those shipments were still worth €617.6 million. That figure is far above the €5.99 million of medicines moving from Russia to the EU in July, even though the two values cover different reporting periods and should not be treated as a direct like-for-like comparison.

For Russian manufacturers, the July result shows that access to the EU market continues and that export revenue can rise rapidly from a relatively small base. For European producers and distributors, Russia remains a much larger destination than the EU is for Russian medicines. The central question for traders and investors is therefore whether July represents the start of sustained growth or a temporary concentration of deliveries. The published figures support a clear rebound, but the absence of volume, product and destination details prevents a conclusion that it was broad-based.